Wall Street analyst estimates for Acrivon Therapeutics, Inc. Common Stock (ACRV): consensus price target, buy/hold/sell recommendations and forecasts for revenue, EPS and EBITDA for the upcoming fiscal years.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool.
Analyst Consensus
| Strong Buy | 0 |
| Buy | 9 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 10 |
| Avg rating (1-5) | 0.90 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-12 | $-0.45 | ||
| 2026-08-12 | $-0.43 | $-0.50 | +14.4% |
| 2026-05-13 | $-0.49 | $-0.49 | +0.0% |
| 2026-03-19 | $-0.49 | $-0.49 | +0.0% |
| 2025-11-13 | $-0.47 | $-0.57 | +17.5% |
| 2025-08-13 | $-0.55 | $-0.57 | +3.5% |
| 2025-05-14 | $-0.51 | $-0.57 | +10.5% |
| 2025-03-27 | $-0.60 | $-0.69 | +13.0% |
Valuation Ratios
| Price / Book | 0.81 |
| EV / EBITDA | -0.66 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | $13000 | 0 | 0 | $536000 | $1.0M | $1.4M |
| Gross Profit | -$13000 | 0 | 0 | -$536000 | -$1.0M | -$1.4M |
| Research & Development | $1.9M | $13.7M | $23.9M | $45.5M | $64.0M | $60.0M |
| Selling, General & Admin | $1.3M | $2.5M | $8.7M | $21.2M | $25.2M | $24.1M |
| Operating Expenses | $3.2M | $16.2M | $32.7M | $66.7M | $88.2M | $82.8M |
| Operating Income | -$3.2M | -$16.2M | -$32.7M | -$67.2M | -$89.2M | -$84.1M |
| EBITDA | -$5.3M | -$16.2M | -$30.8M | -$59.9M | -$79.5M | -$76.5M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$5.3M | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | 0 |
| Net Income | -$5.3M | -$16.2M | -$31.2M | -$60.4M | -$80.6M | -$77.9M |
| EPS | $-0.41 | $-1.26 | $-1.42 | $-2.74 | $-2.10 | $-2.02 |
| EPS (Diluted) | $-0.41 | $-1.26 | $-1.42 | $-2.74 | $-2.10 | $-2.02 |
| Shares Outstanding (Diluted) | $12.9M | $12.9M | $21.9M | $22.1M | $38.3M | $38.5M |
Price
| Price | $1.70 |
| Market Cap | $73M |
| Exchange | NASDAQ |
| Country | US |
Related companies: ATYR · BMEA · CBUS · IMUX · PMVP · RLMD · RPTX
Explore sector: Healthcare · Biotechnology
More sections of ACRV: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks